BRIEF-Bharat Biotech Concludes Final Analysis For Covaxin Efficacy From Phase 3 Clinical Trials

* BHARAT BIOTECH CONCLUDES FINAL ANALYSISFOR COVAXIN® EFFICACY FROM PHASE 3 CLINICAL TRIALS

* BHARAT BIOTECH - EFFICACY ANALYSIS DEMONSTRATES COVAXIN TO BE 77.8% EFFECTIVE AGAINST SYMPTOMATIC COVID19 * BHARAT BIOTECH - EFFICACY ANALYSIS DEMONSTRATES COVAXIN TO BE 93.4% EFFECTIVE AGAINST SEVERE SYMPTOMATIC COVID-19

* BHARAT BIOTECH - EFFICACY DATA DEMONSTRATES COVAXIN TO BE 63.6% PROTECTION AGAINST ASYMPTOMATIC COVID-19 * BHARAT BIOTECH - EFFICACY DATA DEMONSTRATES COVAXIN TO BE 65.2% PROTECTION AGAINST THE SARS-COV-2, B.1.617.2 DELTA VARIANT

Also Read: COVID-19 in children often asymptomatic, 2pc-3 pc infected kids may require hospitalization: VK Paul